DNA copy number alterations (CNAs), including amplifications and deletions, can result in significant changes in gene expression and are closely related to the development and progression of many diseases, especially cancer. For example, CNA-associated expression changes in certain genes (called candidate tumor driver genes) can alter the expression levels of many downstream genes through transcription regulation and cause cancer. Identification of such candidate tumor driver genes leads to discovery of novel therapeutic targets for personalized treatment of cancers. Several approaches have been developed for this purpose by using both copy number and gene expression data. In this study, we propose a Bayesian approach to identify candidate tumor driver genes, in which the copy number and gene expression data are modeled together, and the dependency between the two data types is modeled through conditional probabilities. The proposed joint modeling approach can identify CNA and differentially expressed genes simultaneously, leading to improved detection of candidate tumor driver genes and comprehensive understanding of underlying biological processes. We evaluated the proposed method in simulation studies, and then applied to a head and neck squamous cell carcinoma data set. Both simulation studies and data application show that the joint modeling approach can significantly improve the performance in identifying candidate tumor driver genes, when compared with other existing approaches.
Introduction
Copy number alteration (CNA) is a form of DNA structural change that leads to abnormal numbers of copies in specific DNA regions. CNA is closely associated with the development and progression of many human diseases, especially cancer [1] [2] [3] . CNA could directly affect mRNA expression during transcription (the process of generating mRNA from DNA). For example, genes in deletion regions have less or no copies of DNA, and therefore tend to have lower or no expression. On the other hand, genes in amplification regions have increased numbers of DNA copies and may be over expressed. As a result, the expression level of a gene is, in general, positively correlated with its copy number. For example, studies have shown that, in prostate epithelial cell lines, 51% of over-expressed genes were mapped to the chromosomal regions with DNA gain, and 42% of under-expressed genes were mapped to the chromosomal regions with DNA loss [4] . In breast tumor cell lines, 62% of highly amplified genes show moderately or highly elevated expression [5] . Studies later found similar evidence in several other tumor types [6, 7] .
In cancer research, Vogelstein et al. defined driver genes as genes whose structural or sequence mutations confer a selective advantage to the cancer cell [8] . Although they need not have CNAs or
Statistical models

Modeling copy number data
For copy number data, we adapt the Bayesian HMM proposed by Guha et al. [16] to account for the spatial dependence among neighboring genes in CNA status. Guha's model has four CNA states: copy number loss, copy-neutral state, single copy gain, and amplification (i.e., multiple copy gain). In an ideal situation, the single copy gain in the log 2 space is log 2 .
2
/ 0:58. But, in real applications, the mean of CNAs could be greatly affected by the fact that some patients have certain copy number gains, yet other patients do not. The observed copy number gain at the population level is an average of the patients with copy gain and those without, so it may be hard to clearly distinguish the single copy gain state from the other states at the population level. Therefore, we merge this state with the amplification state in our model.
Let X ij denote the copy number ratio of tumor versus normal samples (in the log 2 space) in the i-th array for gene j , where X ij follows a normal distribution with mean a j and variance 2 xj for i 2 .1; : : : ; I 1 / and j 2 .1; : : : ; J / (i.e., I 1 arrays and J genes in total). For each gene j , D j represents its CNA status:
if gene j is in a normal region
if gene j is in an amplification region Furthermore, we assume that for gene j , given the CNA status D j , the mean measurement a j follows a normal distribution, namely, where˛ < 0 <˛C. If gene j is in a normal region, its mean log-ratio should be close to 0, and so the mean of a j is fixed at 0 for these genes. Here, we do not force the a j s to be exactly zero because real data suggest that the mean log-ratios could vary from zero.
We used a hidden Markov chain to model the spatial dependence of D j s among adjacent genes on chromosome. The CNA status D j of gene j is a hidden state that can not be observed directly, whereas the observed copy number ratio X ij depends on the unobserved D j that takes an integer value ( 1, 0, 1), and D j only depends on D j 1 . Let ƒ be the transition matrix of the HMM, 
Modeling gene expression data
Let Y ij denote the expression intensity ratio of tumor sample versus normal sample (in log 2 space) in the i-th array for gene j , where Y ij follows a normal distribution with mean b j and variance 2 yj , for i 2 .1; : : : ; I 2 / and j 2 .1; : : : ; J / (i.e., I 2 arrays and J genes in total). For each gene j , the indicator variable E j describes its gene expression status:
Furthermore, it is assumed that given the expression status E j , the mean expression level of gene j follows a normal distribution, namely,
whereˇ < 0 <ˇC. We assume that genes in different CNA regions have different probabilities of being over expressed and under expressed. Therefore, we set up a conditional probability matrix ‰ to link the copy number and gene expression data,
where the .s; t /th element in ‰ is defined by
For the s-th row of ‰:
Let .E j ; E j 0 ; E j C / be the indicator vector of E j , where .E j ; E j 0 ; E j C / D .1; 0; 0/, .0; 1; 0/ and .0; 0; 1/ represent E j D 1; 0; 1, respectively. Then .E j ; E j 0 ; E j C / j D j D s; ‰ multinomial.1; ' 1js ; ' 0js ; ' 1js /
The full probability model
Let ‚ denote all the parameters involved, X denote the copy number data, and Y denote the gene expression data. We assume all the variance components are independent. Let .xj ; 2 / denote the probability density function (PDF) of a normal distribution with mean and variance 2 , evaluated at x. Let . / denote a general (hyper) prior distribution. Then the full probability model is given by 
We presented other details for full conditional posterior distributions in the Appendix.
Prior specification
For the population-level means, we use independent noninformative flat priors; that is,˛ U. L˛; 0/, C U.0; L˛/,ˇ U. Lˇ; 0/ andˇC U.0; Lˇ/. We assign independent conjugate inverse gamma priors, IG.u; v/, to all the variance components. For row vectors ! s of the transition matrix ƒ and ! ' s of the conditional probability matrix ‰.s D 1; 0; 1/, we consider a Dirichlet prior Dirichlet. E ı). As to specification of the hyperparameters involved, we can specify the upper bounds
so that the corresponding flat priors provide a sufficient coverage to all possible values of the means. Another way to specify L˛(or Lˇ) conservatively is to find the mean and standard deviation (SD) of all
We choose the hyperparameters of the inverse gamma priors u and v to make the priors very vague, for example, u D 0:01 and v D 0:01. For the Dirichlet prior, we choose E ı D .1; 1; 1/ so that they are noninformative.
Statistical inference and implementation
Because the full posterior conditionals are all known distributions (refer to the Appendix), we can use a Gibbs sampler to draw posterior samples readily from the joint posterior distribution f .‚jX; Y/. We ran 8000 iterations for each data set in our numerical experiments. We used the first 4000 iterations as burn-in samples, and iterations 4001-8000 were used as posterior samples for statistical inference. We also tried 20,000 iterations in our simulation studies, and the results were similar.
The goal of the analysis is to identify the driver genes, which have both abnormal expressions and CNAs. We can use the posterior probabilities of E j s and D j s to detect differentially expressed (DE) genes and genes with CNAs, respectively. For driver genes, we used the posterior probabilities P r.E j D 1&D j D 1/ and P r.E j D 1&D j D 1/. In the HNSCC data example, we selected genes with P r.E j D 1&D j D 1/ > 0:8 or P r.E j D 1&D j D 1/ > 0:8 as the identified driver genes.
For convergence detection, we used trace plots. We also ran several chains with different initial values and then used the Gelman and Rubin's statistics [32] to confirm that the chains were converged. To check the sensitivity of the Bayesian analysis, we tested different values of hyperparameters v, u, ı , ı 0 , and ı C , and the results were similar, indicating that the analysis is robust against different values of hyperparameters.
We implemented our approach with C++ and the statistical part of GNU scientific library. It would take about 5 min to get results when the proposed method is applied to the simulated data with 1000 genes, 15 copy number arrays, and 15 gene expression arrays. The time would increase to 1 h for the real data application in HNSCC data, where we have 10,844 genes with same number of arrays. We provide the integrative analysis software (fully integrated Bayesian approach) as a web-based service on our Galaxy server (http://galaxy.qbrc.org/?tool_id=FIBA).
Simulation
We conducted eight simulation studies to examine the performance of the proposed method. In studies 1-3, we compared the performance of our joint modeling approach in detecting driver genes with four existing methods, edira [29] , SIM [30] , intCNGEan [27] , and DLMM [31] , all developed for integrative analysis of copy number and gene expression data. Table A .1 summarizes the implementation details for different methods. Next, studies 4 and 5 evaluated our model with data generated from underlying models that are different from the assumed model. We found that, overall, our approach outperformed the other four methods. Furthermore, to shed light on how our integrated Bayesian approach leads to superior performance and to further understand its behavior, we conducted studies 6-8, in which we compared the proposed joint modeling approach with the analysis using one data source only.
In all of the simulation studies, we simulated a chromosome with 1,000 genes, which has two amplification regions and two deletion regions. Each of the four regions contains 50 genes, and the remaining 800 genes are in the normal regions. Fifteen arrays were simulated for both copy number and gene expression data, following the HNSCC data set in our application.
Comparison in detecting candidate tumor driver genes
Here, we considered three different levels of association (strong, moderate, and zero) between the copy number and gene expression data. Then, we investigated how the association level affects the relative performance of the five methods, edira, SIM, intCNGEan, DLMM, and our joint modeling approach.
Study 1 is a relatively ideal scenario, where the gene expression is strongly dependent on the CNA status. Specifically, 80% of genes in amplification regions are over expressed, and 80% of genes in deletion regions are under expressed; whereas among genes in normal regions, 10% of genes are over expressed, and 10% of genes are under expressed. All other genes are equally expressed. In study 2, we assume a moderate level of association. Specifically, 50% of genes in amplification regions are over expressed, 50% of genes in deletion regions are under expressed, 10% over expressed and 10% under-expressed genes in normal regions, and all other genes are equally expressed. In study 3, we assume there is no association between copy number and gene expression data; that is, we randomly select 10% of genes as over-expressed genes and another 10% of genes as under-expressed genes, so that the gene expression status E j is independent of the CNA status D j . For a summary of the association setups, see Table I. For copy number data, we generated X ij from N.a j ; 1:0 2 / for i D 1; : : : ; 15, where a j N.0; 0:4 2 / for genes in the normal regions, a j N. 0:6; 0:6 2 / for genes in the deletion regions, and a j N.0:6; 0:6 2 / for genes in the amplification regions. For gene expression data, we generated Y ij from N.b j ; 1:0 2 / for i D 1; : : : ; 15, where b j N.0; 0:4 2 / for equally expressed genes, b j N. 1; 0:6 2 / for under-expressed genes, and b j N.1; 0:6 2 / for over-expressed genes. We estimated all of the parameter values used here from the HNSCC data set in our data application (distributions of the real and simulated data sets are presented in the Figure A.1). Figure 1 reports the receiver operating characteristic (ROC) curves for the joint model, edira, SIM, intCNGEan, and DLMM in simulation studies 1-3. The joint model performs much better than all of the other approaches in detecting driver genes when there is a strong association between the copy number and gene expression data (study 1, Figure 1(a) ). Similarly, in study 2, where there is a moderate Table I . The conditional probability matrix ‰ for simulation studies 1 to 3 and 6 to 8.
Studies 1 and 6
Studies 2 and 7 Studies 3 and 8 Comparison of receiver operating characteristic curves for the proposed joint model, edira, SIM, intCNGEan, and DLMM under three different levels of association (strong, moderate, and zero) between the copy number and gene expression data. The receiver operating characteristic curves were calculated by ranking the genes according to the measurement scores summarized in Table A .1, and comparing the gene rankings with the simulation truth.
association, the proposed joint model also outperforms edira, SIM, intCNGEan, and DLMM ( Figure 1(b) ). Finally, the joint model still performs slightly better than the other four methods even when there is no association between the two data sources (Figure 1(c) ). In summary, the proposed joint modeling approach improves the performance of detecting the candidate tumor driver genes, and the improvement appears to increase as the association between the copy number and gene expression data increases. In order to evaluate the performance of our model with data generated from underlying models different from our proposed model, we designed studies 4 and 5. To better mimic the real data scenario, study 4 differs from the assumed model in the following ways:
(1) For CNA data, we set different alteration levels. Particularly, we set the means of the CNA log ratios in the first amplification region to be from N.0:9; 0:6 2 /, whereas that of the second amplification region is from a N.0:6; 0:6 2 /. We did the same thing to deletion regions, by simulating the means of CNA log ratios of the first deletion region to be from N. 0:9; 0:6 2 /, whereas that from the second deletion region is from N. 0:6; 0:6 2 /. In this way, we can test whether the proposed method has flexibility to accommodate different levels of alterations. (2) We simulated the CNA from the individual patient level. For each amplified region, it has 60% probability to be amplified in each individual sample and the same for the deleted region. This reflects the fact that the alteration occurs at the individual level; that is, some patients have the alterations, while others do not. (3) For a gene located in an amplified region for a specific patient, it has 60% probability to be over expressed in the patient. Similarly, for a gene located in a deleted region for a specific patient, it has 60% probability to be under expressed in the patient. This modification reflects the fact that some driver genes may not lead to changes in gene expression level.
In order to study the robustness of our proposed method against the normal assumption, we used a t mixture distribution [33] , instead of a normal mixture distribution, in study 5 to simulate the data, while keeping the other settings the same as in study 4. Particularly, the a j jD j 's in the CNA data were generated from a t distribution with degrees of freedom 5 and location parameter equal to˛ , 0, and˛C, respectively, for D j equals to 1, 0, and 1. We chose the location parameters so that the sample mean of a j jD j 's was the same as the previous settings. Similarly, b j jE j 's in the gene expression data were generated from a t distribution with degrees of freedom 5 and location parameter equal toˇ , 0, anď C , respectively, for E j equals to 1, 0, and 1. We reported the ROC curves for all five methods in simulation studies 4 and 5 in Figure 2 , and the area under the curves (AUCs) of different methods were summarized in Table II (the simulation for each study were repeated ten times; the means and SDs of AUCs were reported there). We can see that when data were not generated from the assumed model, the joint modeling approach still outperformed the other methods in studies 4 and 5. 
Understanding the behavior of the joint modeling approach
We conjecture that the observed superior performance of the proposed method comes from explicitly modeling the association between the two types of data sources through an integrated Bayesian approach. To aid our intuition, in simulation studies 6-8, we examined the performance of the proposed approach in detecting DE genes and genes with CNAs under different association levels, and compared them with those using either copy number or gene expression data alone. To make a direct comparison, we used the HMM described in Section 2.1 for copy number data alone (named CN alone). We also applied edira for CNA detection to copy number data alone. (Note that the other software (SIM, intCNGEan, and DLMM) does not provide the CNA detection results from the single data source analysis.) For gene expression data, we compared the proposed method with its Bayesian counterpart using the hierarchical model described in Section 2.2 (named GE alone), as well as a popular method SAM-t [34] . None of the edira, SIM, intCNGEan, and DLMM methods can provide results for DE gene detection. For the method GE alone, the conditional probability matrix ‰ becomes a vector ! ' D .' 1 ; ' 0 ; ' 1 /, which is independent of the CNA status. Again, for both CN alone and GE alone, we specified the same noninformative priors, and used Gibbs samplers to draw samples from the posterior distributions, as in the proposed method. In this way, the advantage of the Bayesian joint modeling, if any, can be shown through this direct comparison. As summarized in Table I , simulations 6-8 are for strong, moderate and no association between copy number and gene expression data, respectively, which are the same as in simulations 1-3. We also kept the parameter settings unchanged, except for the noise level in the copy number data, which increases from a D aC D 0:6 and a0 D 0:4 in settings 1-3 to a D aC D 1:0 and a0 D 0:8 in settings 6-8, in order to further test the robustness of our Bayesian method. (Note that in these new settings, DLMM did not perform properly, because the noise level was too high for DLMM to converge.)
To examine the behavior of the proposed method under this elevated noise level, we report the mean and SD) of the posterior samples for the joint model parameters from simulation studies 6-8 in Figure A .3. Also, Table A .2 provides the summary statistics of the posterior samples for the conditional probability matrix ‰ in simulation study 6 as an example. We find that all of the 95% credible Next, we compare the joint model with CN alone, edira, SAM-t, and GE alone, using ROC curves under the three different association levels. Figure A.2(a) shows the ROC curves for detecting genes with CNAs, and Figure A.2(b) presents those for detecting DE genes (no matter over or under expressed) in study 6 (strong association). In this study, the joint model performs much better than using either copy number or expression data alone. Similarly, in study 7 (moderate association), the joint model outperforms the analysis using either copy number or gene expression data alone ( Figure A.2(c) and (d) ), but the improvement is not as large as in study 6. Finally, the joint model performs similarly to that using either data source alone ( Figure A. 2(e) and (f)) in study 8 (no association), which indicates that even if there is no conditional dependency, the proposed method provides a reliable performance. In summary, when there is a positive association between copy number and gene expression data, the joint modeling approach can take advantage of this feature, via an integrated Bayesian approach, to improve the performance in detecting both DE genes and genes with CNAs, leading to the superior performance in identifying candidate tumor driver genes.
Application to head and neck squamous cell carcinoma data
In cancer research, most tumor cells are characterized by CNAs, such as regional or focal amplifications/deletions in chromosomes. Although some driver genes might not lead to expression changes at the mRNA level, a gene is likely to be a tumor driver gene if its CNA-associated expression change alters the transcriptional activities of many downstream genes and leads to cancer. The proposed method can integrate the information from both copy number and gene expression data to better identify candidate tumor driver genes. In this study, we applied our method to a HNSCC data set in order to demonstrate the potential advantages of the joint modeling method.
We downloaded the HNSCC data set from Louhimo et al. 2012 [35] , which contains the gene expression (Affymetrix Human Exon 1.0 microarrays) and copy number (Agilent Human 244A comparative genomic hybridization microarrays) data measured in 15 cancer cell lines and one normal control line. We used the 10,844 genes measured in both copy number and gene expression microarray platforms. We aligned and sorted all genes by their chromosome locations. We used the log 2 ratios between the tumor samples and the control sample as input data for the proposed Bayesian joint model. We used the posterior probability P r.E j D 1&D j D 1/ or P r.E j D 1&D j D 1/ as a criterion to identify candidate tumor driver genes, and then applied Ingenuity Pathway Analysis to study the biological functions of identified genes. Interestingly, we identified 'cancer' as the top hit of diseases and disorders for both under-expressed (Table A. 3 ) and over-expressed genes (Table A. 4) , which indicates that the proposed method could identify biologically meaningful genes. Figure 3 shows the copy number profile (a) and gene expression profile (b) along chromosome 9. Clearly, there is a copy number deletion region near 22 MB. The joint modeling approach identified two tumor driver genes, CDKN2A and CDKN2B, both located in a copy number deletion region with under expression in the tumor samples, compared with the control sample. Studies [36, 37] that under expression of CDKN2A through homozygous deletion or promoter hypermethylation leads to HNSCC. CDKN2B is one of the strongest genetic susceptibility loci for HNSCC [38] . In addition, both CDKN2A (p16) and CDKN2B are known to be important tumor suppressor genes in other cancer types, so both genes are likely to be the true driver genes for HNSCC. Another interesting gene, C9ORF53, has an even lower CNA level than both CDKN2A and CDKN2B, but the expression of C9ORF53 gene is not under expressed in tumor samples. Therefore, it was not identified as a driver gene by the joint modeling approach, indicating the advantage of integrating copy number and gene expression data in identification of candidate tumor driver genes. We show the scatter plots of copy number and gene expression across 15 tumor cell lines for CDKN2A, CDKN2B, and C9ORF53 in Figure 4 . We can see from Figure 4 that both CDKN2A and CDKN2B have CNA-associated expression changes, but C9ORF53 does not. We also applied edira, SIM, intCNGEan, and DLMM methods to this data set. DLMM identified C9ORF53 (score 0.124, rank 1) as the most likely potential gene associated with copy number deletion on chromosome 9, followed by CDKN2A (score 0.108, rank 3) and CNKN2B (score 0.032, rank 23). Similarly, both edira and SIM identified all three of the genes CDKN2A, CDKN2B, and C9ORF53 as driver genes. But intCNGEan did not identify any of them with its default setting. These results suggest that our approach performs better in identifying candidate tumor driver genes, compared with the other existing methods.
Discussion
Recently, studies have proposed several methods to integrate copy number and gene expression data, especially for identifying candidate tumor driver genes [24] [25] [26] [27] [28] . However, most of them focused on either the overlap between genes with CNAs and expression changes or the correlation between CNAs and expression changes, which might not efficiently capture the wide-range and probabilistic relationships between CNAs and gene expression changes in a complex genomic context. In this study, we propose to model the dependency of gene expression change on CNA status through conditional probabilities under a fully integrated Bayesian framework. By modeling the two types of data simultaneously and capturing the probabilistic relationship between them, we can borrow strength across the different data types and improve the statistical inference for each type of data, which leads to better identification of candidate tumor driver genes. Both simulation studies and a data application have shown that the joint modeling approach compared very favorably with other existing approaches, edira, SIM, intCNGEan, and DLMM; and, more importantly, it may reveal novel tumor driver genes as potential therapeutic targets for cancer treatments.
Among the five methods (edira, SIM, DLMM, intCNGEan, and the proposed), all developed for integrative analysis of copy number and gene expression data, we note that the proposed method and DLMM share several common characteristics: (i) both of them rely on model-based Bayesian approaches for coherent inference; (ii) both adopt formal Bayesian hierarchical setups for modeling gene expression and copy number data, respectively; and (iii) both explicitly model spatial patterns to account for spatial dependence existing in copy number data. All of these features are attractive, leading to improved detection of candidate tumor driver genes, as opposed to purely algorithm-based ad hoc approaches. However, there exist major differences between the two, which may explain their performance difference, especially for data with high noise levels. First, DLMM takes a segmentation-based approach to model spatial dependence in the copy number data, and the breakpoint arrangement is updated by reversible jump Markov chain Monte Carlo, which needs a build-in Metropolis-Hastings algorithm. In contrast, we adapted an HMM to model spatial dependence, which has led to a much simpler Gibbs sampler with known distributions for all full posterior conditionals. The algorithm is easy to implement through direct sampling, converges quickly, and appears to be robust to high noise levels. DLMM, because of its complexity, tends to be more sensitive, and usually converges more slowly. Second, DLMM does not directly distinguish the direction of changes; that is, its status variables (Z and W ) for aberrant copy number and differential gene expression are binary (0 or 1) instead of three states ( 1, 0, C1) . Therefore, it takes complicated extra steps that rely not only on Z and W but also on several other continuous variables, in order to calculate the over-expression and under-expression scores. Also, because of the binary setup of Z or W , DLMM has to use a common distribution for genes with any changes for each type of data, without explicitly distinguishing genes with positive changes from those with negative changes. This might cause loss of efficiency, besides the extra effort in inference, when compared with our proposed method.
Whereas CNAs in some genes are constitutively altered in some cancers, those in other genes are only altered in some individual patients. Currently, most computational methods for copy number data are focused on detecting CNA at the individual level. In this study, we attempt to identify the CNA at a population level. Therefore, in our model, the CNA status only depends on genes, not individual subjects. By doing so, the model is more robust and can converge quickly, as we have better statistical power to detect the candidate tumor driver genes at the population level. On the other hand, our model cannot detect the CNA and candidate tumor driver genes for each individual. With some relatively simple modifications, our model can be extended to detect the candidate tumor driver genes for individuals, but the statistical power might be an issue. As we found in the simulation studies, the DLMM method, which models the CNA status at the individual level, only converges when the noise level in copy number data is relatively low.
Appendix
For the s-th row of the transition matrix ƒ, s D 1; 0; 1, we have
where ı , ı 0 and ı C are chosen properly so that the priors are noninformative, and 
where
I.E j D t jD j D s/ for s D 1; 0; 1 and t D 1; 0; 1
and we define 
, and Deletion, and Neutral (Ampli., Del., and Neut.) present the CNA density plots in amplification regions, deletion regions, and neutral regions in simulation data, respectively. Mix presents the overall CNA density plot in simulation data. Real data presents the density plot for real dataset. Table A .2. Summary statistics of posterior samples for the conditional probability matrix ‰ in study 6. For E j , j D 1; ; J , We showed the distributions of the real data set and simulation data sets in studies 1-3 in Figure A. 1.
